Telomir Pharmaceuticals Submits IND for Lead Cancer Drug Telomir-1 in Triple-Negative Breast Cancer
TELO is trading near its 52-week low of $1.05 (8.6% above the low).
Summary
Telomir Pharmaceuticals announced the submission of an IND application to the FDA for its lead investigational candidate, Telomir-1, for the treatment of advanced and metastatic Triple-Negative Breast Cancer.
Key Events · Product Development and Regulatory · TELO
-
IND Application Submitted
Telomir Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn).
-
Targeting Triple-Negative Breast Cancer
The lead candidate, Telomir-1, is intended for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).
-
Phase 1/2 Trial Planned
Subject to FDA clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy in TNBC patients.
-
Preclinical Efficacy and Safety
Preclinical studies showed Telomir-Zn reduced tumor growth and metastatic dissemination in TNBC models, with no treatment-related adverse or dose-limiting toxicities observed in GLP safety studies.
Analysis · TELO · Life Sciences
Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn), its lead candidate for advanced and metastatic Triple-Negative Breast Cancer. This is a critical milestone for the company, especially given its recent 'going concern' warning disclosed in the 10-K on March 17, 2026, and the highly dilutive acquisition approved on March 27, 2026. The successful clearance of this IND and subsequent initiation of a Phase 1/2 clinical trial would provide a much-needed positive catalyst and demonstrate progress in their pipeline, which is essential for a small biotech facing financial challenges. Investors should monitor FDA feedback and the planned trial initiation for further developments.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELO was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.2M. The 52-week trading range was $1.05 to $4.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.